Oral thin films are sublingual or buccal drug delivery systems that are placed on the tongue or inner cheek. They rapidly dissolve to release the active pharmaceutical ingredient which is absorbed directly into the bloodstream, bypassing the gastrointestinal tract and liver. This results in the faster absorption of the drug, greater bioavailability, and quick onset of action. Oral thin films are very convenient and easy to administer, without the need of water compared to tablets and capsules. Their portability and fast dissolving nature makes them popular for emergency drugs, pediatric, and geriatric cases. This trend is fueling growth of the global oral thin films market in the coming years.

Market Dynamics:

Emerging technologies to produce thinner and faster dissolving films, increasing preference for convenient oral dosage forms, and rising demand for pediatric and geriatric dosage forms are some of the key drivers propelling the oral thin films market. Portable packaging and long shelf life without refrigeration requirement is boosting the popularity of thin films in developing regions. Manufacturers are investing in new polymer films and saliva-activated adhesives to develop novel products with enhanced stability and taste masking capacity. For instance, in May 2021, a study published by ResearchGate highlights the growing preference for convenient oral dosage forms, indicating an increased demand for pediatric and geriatric formulations. Children's medicine preferences in Europe are influenced by age, experience, and health, rather than gender. Taste and ease of swallowing are important factors, with liquid medicine favored by younger, healthier children, and pills preferred by older or chronically ill kids. Less common forms like dissolvable films or granules are less popular. Country-specific differences exist, with Spanish children preferring liquid medicine and Dutch children favoring small pills. These insights boost the development of preferred oral dosage forms, emphasizing the need for convenient oral options in pediatric and geriatric care.

Key Features of the Study:

• This report provides an in-depth analysis of the global oral thin films market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global oral thin films market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Aquestive Therapeutics Inc., IntelGenx Corp., LTS Lohmann Therapie- Systeme AG, NAL Pharma, ZIM Laboratories Limited.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global oral thin films market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global oral thin films market.

Detailed Segmentation-

• By Product
  
  • Sublingual Film
  • Fast Dissolving Dental/Buccal Film
• By Disease Indication
  
  • Schizophrenia
  • Migraine
  • Opioid Dependence
  • Nausea & Vomiting
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Aquestive Therapeutics Inc.
  • IntelGenx Corp.
  • LTS Lohmann Therapie-Systeme AG
  • NAL Pharma6.
  • ZIM Laboratories Limited
  • Sunovion Pharmaceuticals, Inc
  • Cure Pharmaceutical
  • L.Pharm
  • Viatris
  • MonoSol Rx
  • Indivior
  • ALLERGAN
  • IntelGenx:
  • BioAlliance Pharma
  • Paladin Labs
  • Labte